Keloid is benign fibroproliferative dermal tumors with unknown etiology. Recently, a genome-wide association study (GWAS) in Japanese population has identified 3 susceptibility loci (rs873549 at 1q41, rs940187 and rs1511412 at 3q22.3, rs8032158 at 15p21.3) for keloid. In order to examine whether these susceptibility loci are associated with keloid in the Chinese Han population, twelve previously reported SNPs were selected for replication in 714 cases and 2,944 controls by using Sequenom MassArray system. We found three SNPs in two regions showed significant association with keloid in the Chinese Han population: 1q41 (rs873549, P = 3.03×10？33, OR = 2.05, 95% CI: 1.82–2.31 and rs1442440, P = 9.85×10？18, OR = 0.56, 95% CI: 0.49–0.64, respectively) and 15q21.3 (rs2271289 located in NEDD4, P = 1.02×10？11, OR = 0.66, 95% CI: 0.58–0.74). We also detected one risk haplotype AG (P = 1.36×10？31, OR = 2.02) and two protective haplotypes of GA and AA (GA, P = 1.94×10？19, OR = 0.53, AA, P = 0.00043, OR = 0.78, respectively) from the two SNPs (rs873549 and rs1442440). Our study confirmed two previously reported loci 1q41 and 15q21.3 for keloid in the Chinese Han population, which suggested the common genetic factor predisposing to the development of keloid shared by the Chinese Han and Japanese populations.
References
[1]
Brown JJ, Bayat A (2009) Genetic susceptibility to raised dermal scarring. Br J Dermatol 161: 8–18.
[2]
Phan TT, Lim IJ, Bay BH, Qi R, Longaker MT, et al. (2003) Role of IGF system of mitogens in the induction of fibroblast proliferation by keloid-derived keratinocytes in vitro. Am J Physiol Cell Physiol 284: C860–869.
[3]
Kelly AP (2004) Medical and surgical therapies for keloids. Dermatol Ther 17: 212–218.
[4]
Bayat A, McGrouther DA, Ferguson MW (2003) Skin scarring. Bmj 326: 88–92.
[5]
Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A (2008) The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg 61: 1049–1058.
[6]
Marneros AG, Norris JE, Watanabe S, Reichenberger E, Olsen BR (2004) Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol 122: 1126–1132.
[7]
Bayat A, Arscott G, Ollier WE, McGrouther DA, Ferguson MW (2005) Keloid disease: clinica relevance of single versus multiple site scars. Br J Plast Surg 58: 28–37.
[8]
Marneros AG, Krieg T (2004) Keloids–clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges 2: 905–913.
[9]
Shih B, Bayat A (2010) Genetics of keloid scarring. Arch Dermatol Res 302: 319–339.
[10]
Bayat A, Bock O, Mrowietz U, Ollier WE, Ferguson MW (2003) Genetic susceptibility to keloid disease and hypertrophic scarring: transforming growth factor beta1 common polymorphisms and plasma levels. Plast Reconstr Surg 111: 535–543; discussion 544–536.
[11]
Bayat A, Bock O, Mrowietz U, Ollier WE, Ferguson MW (2004) Genetic susceptibility to keloid disease: transforming growth factor beta receptor gene polymorphisms are not associated with keloid disease. Exp Dermatol 13: 120–124.
[12]
Lu WS, Zuo XB, Wang ZX, Cai LQ, Zhu F, et al. (2011) Association of HLA haplotype with keloids in Chinese Hans. Burns 37: 794–799.
[13]
Kruglyak L (1999) Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet 22: 139–144.
[14]
Nakashima M, Chung S, Takahashi A, Kamatani N, Kawaguchi T, et al. (2010) A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet 42: 768–771.
Brown JJ, Ollier W, Arscott G, Ke X, Lamb J, Day P, Bayat A (2008) Genetic susceptibility to keloid scarring: SMAD gene SNP frequencies in Afro-Caribbeans. Exp Dermatol 17: 610–613.
[17]
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
[18]
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
[19]
Kumar S, Harvey KF, Kinoshita M, Copeland NG, Noda M, et al. (1997) cDNA cloning, expression analysis, and mapping of the mouse Nedd4 gene. Genomics 40: 435–443.
[20]
Anan T, Nagata Y, Koga H, Honda Y, Yabuki N, et al. (1998) Human ubiquitin-protein ligase Nedd4: expression, subcellular localization and selective interaction with ubiquitin-conjugating enzymes. Genes Cells 3: 751–763.
[21]
Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, et al. (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129–139.
[22]
Vecchione A, Marchese A, Henry P, Rotin D, Morrione A (2003) The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol 23: 3363–3372.
[23]
Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A (2005) Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 280: 22115–22123.
[24]
Izzi L, Attisano L (2006) Ubiquitin-dependent regulation of TGFbeta signaling in cancer. Neoplasia 8: 677–688.
[25]
Izzi L, Attisano L (2004) Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 23: 2071–2078.
[26]
Bettinger DA, Yager DR, Diegelmann RF, Cohen IK (1996) The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 98: 827–833.
